# A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

> **NCT03429101** · PHASE1 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 6 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Poziotinib
- **DRUG:** T-DM1

## Key facts

- **NCT ID:** NCT03429101
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-13
- **Primary completion:** 2019-04-17
- **Final completion:** 2019-04-17
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Dose limiting toxicity
- **Last updated:** 2021-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03429101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03429101, "A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03429101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*